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A simple large-scale purification of a2-adrenergic receptor-enriched membranes from human platelets is 
described. Binding of the antagonist [3H]yohimbine is enriched 3-5-fold compared to a crude membrane 
fraction. Binding of low concentrations of the partial agonist 3H-p-aminoclonidine is increased 15-20-fold 
due to a higher binding affinity for the purified membranes. A soluble inhibitor of 3H-p-aminoclonidine 
binding to purified membranes is found even in thrice-washed crude platelet membranes. The guanine 
nucleotides GDP and GTP are found to account for this inhibitory activity. Forskolin-stimulated adenylate 
cyclase activity is also enriched in the purified membrane fraction. Adenylate cyclase activity is inhibited by 
a2-agonist to a comparable extent in all membrane fractions. This membrane preparation should prove useful 
in studies of az-adrenergic receptor mechanisms. 
Introduction 
Catecholamines can produce either activation 
of adenylate cyclase via fl-adrenergic receptors or 
inhibition via a2-receptors [1,2]. Activation of the 
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enzyme by fl-adrenergic receptors has been exten- 
sively studied (see Ref. 3, for review). There are 
significant parallels between the mechanisms of 
receptor-mediated activation and inhibition. Both 
processes require guanine nucleotides [1] and ap- 
pear to be mediated by guanine nucleotide binding 
proteins [3,4]. Gilman and collaborators have pro- 
vided significant insight into the interactions of 
the stimulatory (Ns) and inhibitory (Ni) guanine 
nucleotide binding proteins with each other and 
with the catalytic subunit of adenylate cyclase [5]. 
In order to better understand the interactions of 
et2-adrenergic receptors with the N i protein it 
would be desirable to be able to accurately mea- 
sure agonist and antagonist binding to this recep- 
tor. Few direct comparisons of agonist and 
antagonist binding to a single membrane prepara- 
tion are available [6,7]. This is due in part  to 
difficulties in measurements of agonist binding. 
Many investigators have used a washed crude 
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membrane fraction from human platelets for ot 2- 
receptor binding studies [6-9]. Quantitative analy- 
sis of agonist binding in these preparations has 
been difficult because of low specific and high 
nonspecific binding. The availability of a purified 
plasma membrane preparation for the nicotinic 
eholinergie [10] receptor system has facilitated bio- 
chemical and mechanistic studies of that receptor. 
Human platelets provide a ready source of a 2- 
adrenergic receptors [8.9,11] and many methods 
for purifying plasma membranes from human 
platelets have been reported [11-13]. One study of 
Ctz-agonist binding to a partially purified plasma 
membrane preparation has been published [11]. 
In this report we describe a simple method to 
prepare large amounts of platelet membranes en- 
riched in az-adrenergic receptors. The agonist and 
antagonist binding properties of these membranes 
are characterized. The increase in binding of low 
concentrations of agonists seen for the purified 
membranes in several-fold greater than that for 
antagonists. The persistence of guanine nucleotide 
inhibitors of agonist binding in washed crude 
membranes is demonstrated and may partially ex- 
plain these observations. The purified membrane 
preparation described here should facilitate bio- 
chemical and mechanistic studies of the a2-adren- 
ergic receptor. A preliminary version of this report 
has been presented [14]. 
Materials and Methods 
Human platelet concentrates. Concentrates were 
obtained from the Detroit Red Cross where they 
had been stored at room temperature and used 
within 24 h of collection. Blood was anticoagu- 
lated with CPDA-I (2 g glucose, 1.66 g sodium 
citrate, 206 mg citric acid, 140 mg NaH2PO 4 and 
17.3 mg adenine per 450 cc of whole blood). The 
platelets were unsuitable for human use because of 
breaks in sterile technique, erythrocyte contamina- 
tion or positive antierythrocyte antibody screens. 
Radiochemicals. 3H-p-Aminoclonidine (40.0- 
40.5 Ci/mmol),  and [3H]yohimbine (75.0-82.7 
Ci /mmol)  were obtained from New England 
Nuclear. [a-32p]ATP and [3H]cAMP were from 
Amersham. Radiochemical purity was checked by 
the TLC systems suggested by the manufacturers. 
Drugs and chemicals. Oxymetazoline was a gift 
of Schering Corp. UK 14,304 was a gift of Pfizer 
Ltd. 1-Epinephrine tartrate, yohimbine, phenyl- 
methylsulfonyl fluoride, and nucleotides were from 
Sigma. Forskolin was from Calbiochem-Behring. 
All other chemicals were reagent grade or better 
from standard suppliers. 
Washing and freezing platelets. All steps prior to 
freezing the platelets were performed at room tem- 
perature using plastic tubes and pipettes. Platelet 
concentrates were diluted with an equal volume of 
150 mM NaCI, 1 mM EDTA, 20 mM Tris-HC1 
(pH 7.5), and centrifuged for 10 min at 200 x g to 
remove contaminating erythrocytes. The super- 
natant was carefully decanted and centrifuged for 
20 min at 1500 x g. The platelet pellets were resus- 
pended in the same buffer by gentle trituration 
and pelleted again. The pellets were resuspended 
in 2 ml per unit of buffer containing 50 mM 
Tris-HC1 (pH 7.5), 5 mM EGTA, 0.2 M sucrose. 
These washed platelet pellets were quick frozen in 
a solid CO2/ethanol bath and stored at - 7 0 ° C  
for up to 2 months before use. 
Membrane preparation. Frozen washed platelets 
(10-56 U per preparation) were supplemented with 
sufficient phenylmethylsulfonyl fluoride (0.1 M in 
ethanol) to produce a final concentration of 10 - 4  
M. They were then thawed in a water bath at 15°C 
and immediately chilled on ice. 50 ml batches were 
sonicated twice with a Branson sonifier (micro tip, 
setting 6) for 10 s, chilling for 30-60 s between 
bursts in an ice-salt bath to prevent gel formation. 
The sonicate (15 ml per tube) was layered on a 
discontinuous gradient containing 20 ml of 14.5% 
sucrose (w/w) and 20 ml of 34% sucrose (w/w) 
and centrifuged at 105 000 x g for 3 h in a Beck- 
man Type 35 rotor. The clearly defined interface 
between 14.5 and 34% sucrose contained the puri- 
fied membrane fraction (I membranes). This was 
diluted with two volumes of ice-cold distilled-de- 
ionized water, centrifuged at 105000 x g for 60 
min, and resuspended in a volume of one ml of 
buffer per unit of platelets. The buffer contained 
50 mM Tris-HC1, 10 mM MgC12, 1 mM Tris- 
EGTA (pH 7.6). Aliquots were quick-frozen in a 
solid CO2/ethanol bath and stored at - 7 0 ° C  for 
up to three months without loss of binding activ- 
ity. 
The large pellet (P) from the discontinuous 
gradient was resuspended in 2 ml per unit of the 
same buffer. Aliquots of the total sonicate were 
pelleted at 43000 × g for 20 min to prepare a 
crude membrane fraction (M). These membranes 
were washed thrice more by pelleting and resus- 
pending in 1 ml/unit  of buffer and called washed 
membranes (MW membranes). A washed mem- 
brane fraction similar to this is used by many 
investigators for binding studies. All samples were 
quick frozen and stored at -70°C. 
[311] Yohimbine binding. Binding was measured 
in a final volume of 0.1 ml of buffer containing 50 
mM Tris-HC1, 10 mM MgC12, 1 mM EGTA (pH 
7.6) at room temperature (22-24°C). The reaction 
was initiated by addition of membranes and 
stopped after 30-60 min by dilution with 3 ml of 
buffer (50 mM Tris-HC1, 10 mM MgC12 (pH 7.6)). 
This was immediately poured over Whatman 
G F / C  filters, filtered under vacuum, and washed 
twice with 10 ml of the dilution buffer (room 
temperature). Filters were dried for 15 min under 
a heat lamp and counted in 4 ml OCS (Amersham) 
at 32-42% efficiency. Nonspecific binding was 
determined in the presence of 10 -5 M yohimbine 
and was less than 7% of total binding for I mem- 
branes and less than 10% for MW and P mem- 
branes [15]. 
SH-p-Aminoclonidine binding. Binding was mea- 
sured in a final volume of 1 ml of buffer contain- 
ing 50 mM Tris-HC1, 10 mM MgCI 2, 1 mM 
EGTA (pH 7.6) at room temperature (22-24°C). 
Aliquots of membranes were diluted at least 20-fold 
in the same buffer and were warmed for 2 min in a 
23°C bath before being added to the radioligand. 
The reaction was stopped at exactly 20 min by 
addition of 5 ml of buffer containing 50 mM 
Tris-HC1, 10 mM MgC12 (pH 7.6) followed by 
immediate filtration over Whatman G F / C  filters. 
The filters were washed twice with 10 ml of the 
dilution buffer and radioactivity measured as 
above. Nonspecific binding was determined in the 
presence of 10 -5 M oxymetazoline as described 
[151. 
Analysis of binding data. [3H]Yohimbine bind- 
ing isotherms were analyzed by nonweighted linear 
least-squares fits of Scatchard transformations of 
specific binding. 3H-p,Aminoclonidine binding 
curves were fit using a nonlinear least-squares 
procedure for one- and two-site models [16]. 
Adenylate cyclase assays, Measurement of 
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adenylate cyclase activity and its inhibition by 
a2-agonists was done in buffer containing (final 
concentrations) Tris-HCl, 25 mM (pH 7.6); NaC1, 
100 mM; MgC12, 2.5 mM; EGTA, 1.5 mM; cAMP 
(Tris salt), 1 mM; isobutylmethylxanthine, 0.1 mM; 
GTP, 10 -5 M; phosphocreatine, 5 mM; creatine 
phosphokinase, 50 U/ml;  propranolol 10 -5 M; 
and ATP, 0.2 mM (0.5/~Ci [a-31p]ATP per tube) 
plus the indicated concentrations of drugs. Tubes 
containing epinephrine also contained 0.01% 
sodium ascorbate which was shown to have no 
effect in control experiments. [32p]cAMP formed 
was measured by the method of Salomon et al. 
[17]. Activity was linear to 20 min in the presence 
and absence of epinephrine. Assays were routinely 
conducted for 10-15 min at 30°C. 
Measurement of catecholamine and nucleotide 
content. Frozen membrane fractions were thawed 
on ice. Protein was precipitated by addition of an 
equal volume of 0.8 M HC104 followed by centri- 
fugation in an Eppendorf microfuge at 4°C. Su- 
pernatants were neutralized by addition of KOH 
and KHCO 3. Aliquots were assayed for catechol- 
amine by the radioenzymatic method of Peuler 
and Johnson [18]. Nucleotides were quantitated by 
HPLC on a strong anion-exchange column [19]. 
Miscellaneaous. SDS-gel electrophoresis was 
performed by the method of Laemmli [20]. Lactate 
dehydrogenase was measured by the method of 
Wroblewski and La Due [21]. Protein was de- 
termined by the method of Lowry et al. [22] with 
bovine serum albumin as standard. Na ÷, K ÷- 
stimulated ATPase and acidic phosphodiesterase 
were measured as described [23,24]. All binding 
measurements are means of triplicate determina- 
tions unless otherwise indicated with values ex- 
pressed as mean + S.D. 
Results 
Platelet fractionation 
A well defined membrane fraction (I) appears 
just below the interface between the 14.5% and 
34% sucrose solutions. It is easily aspirated from 
the gradient without disturbing the firm pellet. 
This fraction contains approximately one eighth of 
the total membrane protein. It contains less than 
1-2% of total platelet lactate dehydrogenase indi- 
cating minimal contamination by the cytosolic 
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Fig. 1. SDS-polyacrylamide gel electrophoresis of different 
membrane fractions. Samples of each of the platelet membrane 
fractions containing 100/~g of protein were subjected to SDS- 
polyacrylamide gel electrophoresis according to Laemmli [20]. 
i0% acrylamide gels were used and proteins stained with 
Coomassie blue. The light membranes (I) appear to have rela- 
tively more of the M r 104000 and 129000 bands corresponding 
to the surface associated glycoproteins IIb and III (small 
arrows). The I membranes are depleted of the M r 41800 
protein reported to be actin (large arrow). Molecular weight 
standards from bottom to top (and their apparent Mr) a r e  
carbonic anhydrase (29000), ovalbumin (45000), bovine al- 
bumin (66000), phosphorylase b (97400), ~8-galactosidase 
(116000) and myosin (205000). I, sucrose interface membrane; 
M, crude membrane; MW, washed crude membrane; P, pellet 
membrane. 
fraction. In contrast, the total membrane fraction 
(M), washed membrane fraction (MW) and pellet 
(P) from the sucrose gradient contained 9-31%, 
3-6%, and 13-14%, respectively, of total lactate 
dehydrogenase, indicating more cytosolic con- 
tamination. 
Attempts to measure Na + and K+-stimulated 
or ouabain-inhibited ATPase activity as a plasma 
membrane marker were unsuccessful as has been 
reported by others [13]. Acidic phosphodiesterase, 
another possible plasma membrane marker, was 
found predominantly in the soluble fraction of 
human platelets making it a poor plasma mem- 
brane marker (unpublished data). SDS gel electro- 
phoresis of I membranes shows less of a promi- 
n e n t M  r 41800 protein than is seen in M, MW 
and P membranes (Fig. 1). This protein band has 
been previously associated with actin. The I mem- 
branes are also relatively enriched in a pair of 
diffusely stained polypeptides of M r 104000 and 
129000, which are similar to the M r of the surface 
associated glycoproteins liB and III [25]. 
3H-labeled a2-adrenergic receptor figand binding 
Measurement of the binding of the antagonist, 
[3H]yohimbine, and the agonist, 3H-p-aminoc- 
lonidine, to the various membrane fractions was 
done for twelve different preparations of the puri- 
fied membranes. Single ligand concentrations were 
used; 10 nM [3H]yohimbine which will saturate 
most (more than two-thirds) of the binding sites 
and 3 nM 3H-p-aminoclonidine which should oc- 
cupy predominantly the high-affinity agonist bind- 
ing sites [7,15]. Results shown in Table I indicate a 
3.7-fold purification of [3H]yohimbine binding 
sites in the purified plasma membranes (I) versus 
the crude membrane (M) fraction. Part of this 
purification is probably due to removal of con- 
taminating or loosely bound cytoplasmic proteins 
as there is a 1.5-fold purification from washing the 
membranes alone (MW). The remaining 2.5-fold 
purification may thus be attributed to removal of 
membrane-containing organelles not containing 
the a2-adrenergic receptor. In order to determine 
whether the increase in [3H]yohimbine binding 
was due to a change in the dissociation constant or 
to an increase in the number of binding sites per 
milligram protein, binding isotherms were mea- 
sured (0.5-30 nM [3H]yohimbine). A comparison 
of Scatchard plots of [3H]yohimbine binding to 
the total washed membrane fraction (MW) and the 
interface membranes (I) revealed more binding 
sites in the latter, 253 ___ 80 vs. 530 + 46 fmol /mg 
protein (n = 4 and 8, respectively, data not shown). 
There was no difference in the dissociation con- 
stants for the two membrane fractions, 5.8 + 0.8 
nM and 5.3 + 1.2 nM, respectively. Another con- 
sistent finding was that the total amount of recep- 
tor recovered in the combined I and P fractions 
was approx. 50% more than that in M or MW 
fractions (Table I). 
The 17-fold increase in binding of 3 nM 3H-p- 
aminoclonidine upon comparison of results for M 
and I membranes is even more striking than that 
seen for [3H]yohimbine (Table I). A quantitative 
measure of the discrepancy between agonist and 
antagonist binding is the ratio of 3H-p-amino- 
clonidine bound at 3 nM divided by [3H]yohim- 
bine bound at 10 nM times 100 ( P / Y  ratio). The 
P / Y  ratio is indicative of the fraction of a2-rece p- 
tors binding 3H-p-aminoclonidine with high affin- 
ity. It is lowest in M and P membranes, 5.2 and 
5.5%, respectively. It is highest in I membranes at 
27.1% while MW membranes are intermediate at 
10.8%. 
Complete binding curves were constructed for 
3H-p-aminoclonidine and [3H]yohimbine binding 
to I and MW membranes to explore the origin of 
this discrepancy. Fig. 2 (panels A & B) shows that 
Scatchard plots of [3H]yohimbine binding are lin- 
ear, indicating a single class of binding sites. For 
this particular preparation there was only a 1.5-fold 
greater number of [3H]yohimbine binding sites in 
I vs. MW membranes. 3 H-p-Aminoclonidine bind- 
ing to I membranes is characterized by a nonlinear 
Scatchard plot. Fitting these data with a nonlinear 
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least-squares method gives estimates of 30 
fmol/mg high-affinity sites with a K d of 0.21 nM 
and 327 fmol/mg low-affinity sites with a K d of 
4.8 nM. In contrast, the MW membranes had no 
high-affinity 3H-p-aminoclonidine binding. With 
the small amount of binding to MW, parameter 
estimates are only approximate, but a K d of 41 
nM and Bma X of 420 fmol/mg were obtained. 
Thus, the striking increase in binding of low con- 
centrations of the partial agonist 3H-p-amino- 
clonidine upon purification of the membranes is 
due more to the increase in binding affinity than 
to an increase in the number of binding sites. 
Notably, the K d for binding to MW membranes is 
the same as that seen for I membranes in the 
presence of p[NH]ppG [7,15]. A more detailed 
characterization of the ligand binding properties 
of these purified membranes is reported elsewhere 
[151. 
Origin of reduced agonist binding to crude washed 
membranes 
Many mechanisms could account for the 
reduced affinity of agonist binding in the crude 
washed membranes (MW fraction): different 
receptors for agonist and antagonist, inactivation 
of agonist binding by proteases, degradation of 
labelled ligand, presence of inhibitors of agonist 
binding (e.g. endogenous catecholamines, GTP, or 
sodium ion). The following experiments were done 
to evaluate these mechanisms. 
TABLE I 
[3H]YOHIMBINE AND 3H-p-AMINOCLONIDINE BINDING TO DIFFERENT MEMBRANE FRACTIONS 
Specific [3H]yohimbine (10 nM) and 3H-p-aminoclonidine (3 nM) binding to M, MW, P and I membrane fractions from 12 different 
preparations was measured as described in Materials and Methods. The total unwashed membrane pellet (M) was used to determine 
yields and purification factors for [3H]yohimbine binding. The percent of [3H]yohimbine binding sites also occupied by 3 nM 
3H-p-aminoelonidine is shown as PlY. This is a semiquantitative measure of the amount of high-affinity 3H-p-aminoclonidine 
binding (see text). Yields of 3H-p-aminoclonidine binding sites are not presented because its bindings is not linear with membrane 
concentration (Fig. 3). The amount of membrane used in each assay was typically 0.4-0.8 mg/ml  for M, 0.3-0.7 mg/ml  for MW, 
0.3-0.6 mg/mi  for P and 0.1-0.3 mg/ml  for I. 
Membrane [ 3 H]Yohimbine 3 H-p-Aminoclonidine 
fraction 
Spec. act. Yield Purification Spec. act. P/Y 
(fmol/mg) (%) factor (fmol/mg) (%) 
M 131~19 1 ~  1.0 6.9~ 1.8 5.2±0.9 
MW 160±17 105±25 1.5±0.4 17.1~ 3.2 10.8±1.5 
P 136±22 99~15 1.0±0.1 7.0~ 1.2 5.5~1.0 







t .  











2b0 4b 0 6b0 
["H]Yohlmblne bound (fmole/mg) 
i 
C D 
40 ~ e  
' °  
200 400 660 860 200 400 660 
['H] PAC bound (fmolelrng) 
Fig. 2. Scatchard plots of [3H]yohimbine and 3H-p-amino- 
clonidine ([3H]PAC) binding to the I and MW membrane 
fractions, (A and B) Binding of [3H]yohimbine (1-30 nM) to I 
(panel A) and MW (panel B) membranes was measured as 
described in Materials and Methods. Linear least-squares fits of 
the Scatchard transformations yielded for 1 membranes a K d 
of 9.2 nM and Bma x of 699 fmol/mg protein and for MW 
membranes a K d of 5.1 nM and Bma x of 459 fmol/mg protein. 
As discussed in the text there was no significant difference in 
K d for yohimbine binding to I and MW membranes while the 
B,,=x was significantly higher for the former. (C and D) Bind- 
ing of 3H-p-aminoelonidine (0.2-30 nM) to I (panel C) and 
MW (panel D) membranes was measured as described in 
Materials and Methods. The solid lines are nonlinear least- 
squares fits of the data. A two-site model best fit the binding to 
I while a one-site model adequately fit MW (see text). The 
same scales are used for ordinate and abscissa for all graphs. I, 
sucrose interface membrane; MW, washed crude membrane. 
Fi rs t ,  l i nea r i ty  o f  l igand  b i n d i n g  wi th  i nc rea s ing  
p r o t e i n  c o n c e n t r a t i o n s  was  s tudied.  F o r  the  pur i -  
f ied m e m b r a n e s  (I f rac t ion) ,  b i n d i n g  of  b o t h  
agon i s t  (3 n M  3 H - p - a m i n o c l o n i d i n e )  a n d  a n t a g :  
on i s t  (10 n M  [3 H ] y o h i m b i n e )  were  l inear  to 0 . 4 - 0 . 5  
m g  p r o t e i n / m l  (da t a  n o t  shown) .  In  con t ras t ,  M W  
m e m b r a n e s  show essen t ia l ly  n o  inc rease  in agon i s t  
b i n d i n g  as the  m e m b r a n e  c o n c e n t r a t i o n  is d o u b l e d  
f r o m  0.2 to  0.4 m g  p r o t e i n / m l  (squares ,  Fig.  3B). 
[ 3 H ] Y o h i m b i n e  b i n d i n g  to M W  m e m b r a n e s  
inc reased  l inear ly  wi th  the  a m o u n t  o f  p ro t e in  de-  
sp i te  the  10- fo ld  h ighe r  p r o t e i n  c o n c e n t r a t i o n  ( 2 - 4  
m g / m l )  in the  a n t a g o n i s t  b i n d i n g  assay. Th is  
o b s e r v a t i o n  sugges ted  tha t  an  i n h i b i t o r  o r  in-  
a c t i va t i on  o f  r e c e p t o r  o r  r a d i o l i g a n d  was  the 
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Fig. 3. Effect of mixing I and MW membranes on binding of 
[3H]yohimbine and 3H-p-aminoclonidine.  Binding of 
[3H]yohimbine (10 nM, top) and 3H-p-aminoclonidine (3 nM, 
bottom) to the indicated amount of MW membranes was 
performed in the presence (circles) and absence (squares) of 
0.224 mg of I membranes. [3H]Yohimbine binding was additive 
and linear with respect to protein concentrations. Agonist 
binding to 1 membranes was reduced in the presence of MW 
membranes suggesting that an inhibitor is present in the latter. 
I, sucrose interface membrane; MW, washed crude membrane. 
mechanism. Thin-layer chromatography Of 3H-p- 
aminoclonidine incubated with MW membranes 
for 30 min at 25°C showed no evidence of de- 
gradation of ligand (data not shown). Mixing MW 
and I membranes revealed an actual decrease in 
3H-p-aminoclonidine binding when MW mem- 
branes were added circles (Fig. 3B). [3H]Yohim- 
bine binding increased in an additive manner as 
expected. These observations strongly suggested 
the presence of a selective inhibitor of agonist 
binding present in the thrice-washed platelet mem- 
branes. 
Epinephrine and norepinephrine concentrations 
in the membrane fractions were M 2.5 and 16.4 
nM; MW 1.0 and 2.6 nM; P 2.0 and 17.3 nM and 
I 2.2 and 6.1 nM, respectively. These samples were 
always diluted at least 20-fold prior to measure- 
ment of 3H-p-aminoclonidine binding so there 
should be no effect from endogenous catechola- 
mines. The concentrations of epinephrine and 
norepinephrine present in the MW membranes 
even undiluted, are insufficient to account for the 
inhibitory activity seen. 
The unwashed membranes, M, and even the 
thrice washed crude membranes, MW, contain ap- 
preciable contents of the guanine nucleotides GTP 
and GDP (Table II). The concentrations achieved 
in binding assays with M and MW membranes are 
greater than the IC50 for inhibition of 3H-p- 
aminoclonidine binding (0.6 and 0.9 mM, respec- 
tively, data not shown). The adenine nucleotide 
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content is not sufficient to inhibit agonist binding 
(IC50> 100 #M for ATP and ADP, data not 
shown). The concentrations of GTP and GDP in 
the I membranes are markedly lower, but GDP 
may produce a small amount of inhibition of 
agonist binding when high membrane protein con- 
centrations are used. 
Two additional washes of MW membranes do 
not increase 3H-p-aminoclonidine binding or re- 
duce the inhibition of 3H-p-aminoclonidine bind- 
ing to I membranes (data not shown). If MW 
membranes are pelleted and resuspended after a 
freeze-thaw step, the binding of 3H-p-aminocloni- 
dine increases and the inhibitory activity decreases 
(Table III). This suggests that the soluble inhibitor 
of agonist binding (presumably the guanine 
nucleotides) can be partially removed by washing 
after a freeze-thaw step. 
Distribution of forskolin-stimulated adenylate cyclase 
in membrane fractions 
Adenylate cyclase activity in the different mem- 
brane fractions was measured in the presence of 
10-5 M forskolin (Table IV). The relative enrich- 
ment in adenylate cyclase activity closely parallels 
the enrichment in [3 H]yohimbine binding sites with 
the greatest activity in the I membrane fraction. 
Epinephrine-induced inhibition of adenylate 
cyclase was present in all fractions. The percentage 
of inhibition was greatest in the crude M fraction 
but because of experimental variability, the dif- 
TABLE II 
AGONIST BINDING AND NUCLEOTIDE CONTENT OF MEMBRANE FRACTIONS 
Membrane fractions from two sucrose gradient purifications were analyzed for [3 H]yohimbine and 3 H-p-aminocionidine binding. The 
percentage of sites occupied by the agonist with high affinity was estimated by the P / Y  ratio (see Table I and text). Nucleotide 
content of perchloric acid extracts of the membrane fractions were determined as described in Materials and Methods. Results are 
expressed as #mol/100 pmol [3H]yohimbine binding sites because agonist binding measurements are typically performed at a 
receptor concentration of 50-100 pM. Thus the values presented reflect the concentration of nucleotide in a typical binding assay in 
units of #M. Values in parentheses indicate the range of duplicate determinations. I, sucrose interface membrane; M, crude 
membrane; MW, washed crude membrane; P, pellet membrane. 
Fraction P /  Y 
(~) 
/~ mol/lO0 pmol [ 3 H]yohimbine binding 
GTP GDP ATP ADP 
I 32 (29, 34) 0.07 (0.06, 0.07) 0.5 (0.4, 0.6) 0.4 (0.7, 0.1) 
M 4 (4, 4) 1.9 (1.4, 2.3) 5.4(5.2, 5.5) 11.0(11.0, 11.0) 
MW 11 (6, 16) 0.9 (0.5, 1.4) 2.5(2.4,2.5) 4.3 (3.7, 4.8) 
P 6 (5, 6) 2.1 (1.4, 2.7) 5.7 (5.5, 5.8) 11.7 (11.3, 12.0) 
1.2 (1.7, 0.9) 
26.7 (29.4, 24.0) 
14.0 (12.9, 15.1) 
30.7 (31.7, 29.7) 
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TABLE III 
EFFECT OF WASHED CRUDE MEMBRANE SUPER- 
NATANT ON 3H.p.AMINOCLONIDINE BINDING 
Aliquots of I and MW membranes were thawed and kept at 
4°C. Half of the MW membranes were centrifuged for 30 rain 
at 140000× g. The supernatant (MW supernatant) was col- 
lected and the pellet (MW pellet) resuspended in the same 
volume of buffer containing 50 mM Tris-HC1, 10 mM MgC12, 
1 mM EDTA (pH 7.6). Specific binding of 3 nM 3H-p-amino- 
cionidine to the indicated samples is shown. The expected 
binding is calculated from that seen for I alone, MW alone or 
MW supernatant. Values are means of triplicate determinations 
that differed by less than 10%. I, sucrose interface membrane; 
MW, washed crude membrane. 
Sample Specifically bound 
3 H-p-aminoclonidine (cpm) 
Observed Expected % of 
expected 
I alone 640 640 100 
MW alone 212 212 100 
I + MW 459 852 54 
MW supernatant 0 0 - 
I + MW supernatant 262 640 41 
MW pellet 315 212 149 
I + MW pellet 680 955 70 
ference in percent inhibition among fractions was 
not statistically significant. It has been previously 
reported that adenylate cyclase inhibition is grea- 
test in cude membrane preparations [11]. 
TABLE IV 
ADENYLATE CYCLASE ACTIVITY IN MEMBRANE 
FRACTIONS 
Adenylate cyclase activity was measured in the presence of 
10 -5 M forskolin at 30°C for 10-15 min as described in 
Materials and Methods. Results are mean + S.D. of three ex- 
periments each performed in triplicate. Results for relative 
enrichment were calculated for each membrane preparation 
and the results averaged to give the value reported. I, sucrose 
interface membrane; M, crude membrane; MW, washed crude 
membrane; P, pellet membrane. 
Membrane 
fraction 
Forskolin-stimulated Relative Inhibition by 
adenylate cyclase enrichment epinephrine 






253 5: 74 1.0 39 5:25 
468+127 2.0+0.9 35+15 
383+ 93 1.4+0.2 37+ 2 
823 + 74 3.5 5:1.1 23 + 12 
Basal adenylate cyclase activity in I membranes 
was 30-90 pmol of cAMP produced/rain per mg 
protein (n = 7). Epinephrine (10  - 4  M )  inhibited 
adenylate cyclase by 26-38% (n = 5). The 
pharmacologic specificity of this response was 
studied. Adenylate cyclase activity was 30 + 2, 19 
_+ 1, 19 _+ 2, and 28 _+ 2 pmol/min per mg protein 
in the presence of no additions, 10 - 4  M UK 
14 ,304 ,  10 - 4  M epinephrine and 10 - 4  M epi- 
nephrine plus 10 -5 M yohimbine, respectively. 
The similar inhibition by epinephrine and the 
selective aE-agonist UK 14,304 and the reversal by 
the aE-antagonist yohimbine confirm the a 2- 
adrenergic nature of adenylate cyclase inhibition 
in human platelet membranes [7,11,26]. 
Discussion 
We have described a simple large scale prepara- 
tion of a2-adrenergic receptor-enriched mem- 
branes from human platelets. The 3.7-fold enrich- 
ment of [3H]yohimbine binding in the purified 
membranes (I) is consistent with the expected 
plasma membrane location of a2-adrenergic recep- 
tors. This enrichment reduces the nonspecific bi- 
nding of [3H]yohimbine and allows higher recep- 
tor concentrations to be used in binding assays 
without overloading the glass fiber filters with 
protein. The preparation is highly reproducible 
and stable when frozen in aliquots. It provides a 
means to study a2-adrenergic agonist and 
antagonist binding on the same membrane sample 
under a wide variety of conditions [15]. 
Preliminary studies using the method of Barber 
and Jamieson [12] yielded similar results. How- 
ever, we have found sonication to result in less 
cytosotic contamination as determined by mea- 
surements of lactate dehydrogenase than the 
glycerol lysis method (data not shown). Our 
method differs from that reported by Mooney et 
al. [11] in the use of sonication rather than N 2 
decompression for platelet disruption. This method 
is simpler and easier to scale up to large amounts 
of material (> 60 U). Also we avoid the use of 
colchicine which has been shown to affect the 
guanine nucleotide binding protein of the adeny- 
late cyclase system [27]. 
Our method could be used as an initial step in 
the complete purification of a2-receptor. Struct- 
ural integrity of the receptor may be better pre- 
served by this method because of the absence of 
detergents. The 30-50% yield of a2-receptors is a 
limiting factor, but attempts to improve this with a 
second sonication are in progress. Currently, a 
preparation starting with 40-60 units of platelets 
yields 50-200 pmol of a2-receptors in the enriched 
membranes. The a2-adrenergic receptor has also 
been partially purified from detergent extracts of 
crude human platelet membranes [28]. Recently, 
the a2-adrenergic receptor from a rat adreno- 
carcinoma cell line has been purified to apparent 
homogeneity [29]. The structural integrity of recep- 
tors purified in this manner remains to be de- 
termined. 
The striking finding concerning this purified 
membrane preparation is the markedly greater 
agonist binding than is seen with the crude, washed 
membrane fraction (MW). This is due both to the 
enrichment in receptor binding sites, as reflected 
by [3H]yohimbine binding, and more importantly 
to a marked increase in the affinity of 3H-p- 
aminoclonidine binding. The low affinity of 3 H-p- 
aminoclonidine binding to MW membranes has 
been demonstrated to be due in part to a soluble 
inhibitor of agonist binding. Endogenous catechol- 
amines do not seem to explain these results as very 
low concentrations are present in the assay. Con- 
centrations are lowest in the MW fraction while 
3 H-p-aminoclonidine binding is clearly greatest in 
the I fraction. The persistent association of GDP 
and GTP with the crude washed membranes ap- 
pears to explain the selective loss of agonist bind- 
ing. These data reiterate the difficulty in eliminat- 
ing guanine nucleotides from membrane prepara- 
tions and confirm the utility of sucrose gradient 
methods for preparation of membranes relatively 
free of guanine nucleotides [30]. 
The enrichment of adenylate cyclase activity 
closely parallels that of [3H]yohimbine binding. 
This is expected for two activities presumed to be 
in the same subcellular location (i.e. plasma mem- 
brane). The lack of enhancement in epinephrine- 
induced inhibition of adenylate cyclase is likely 
due to the fact that even in the crude membrane 
fractions, the a2-adrenergic receptor and adenylate 
cyclase catalytic subunit are in the same mem- 
brane vesicles. Thus, the coupling between a2-re- 
ceptor and adenylate cyclase is not substantially 
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changed by removal of non-plasma membrane 
components. The reduced percentage inhibition of 
forskolin-stimulated adenylate cyclase in the puri- 
fied membranes (23 + 12% vs. 35 + 15%) may be 
due to the longer time required for preparation of 
this membrane fraction. In more extensive studies 
of epinephrine-induced inhibition of basal adeny- 
late cyclase, however, a larger percentage inhibi- 
tion was seen (31 + 5%). 
The partially purified platelet plasma mem- 
brane preparation described in this paper may 
represent a useful step in purification of the a 2- 
adrenergic receptor. It also provides a reproduci- 
ble system for studies of the mechanisms of a 2- 
adrenergic agonist binding and responses in the 
membrane environment. 
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